KR102295125B1 - 크론병과 연관된 tnfsf15와 dcr3의 변이체 - Google Patents

크론병과 연관된 tnfsf15와 dcr3의 변이체 Download PDF

Info

Publication number
KR102295125B1
KR102295125B1 KR1020157034355A KR20157034355A KR102295125B1 KR 102295125 B1 KR102295125 B1 KR 102295125B1 KR 1020157034355 A KR1020157034355 A KR 1020157034355A KR 20157034355 A KR20157034355 A KR 20157034355A KR 102295125 B1 KR102295125 B1 KR 102295125B1
Authority
KR
South Korea
Prior art keywords
seq
variants
tnfsf15
delete delete
locus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157034355A
Other languages
English (en)
Korean (ko)
Other versions
KR20160009582A (ko
Inventor
더모트 피. 맥거번
Original Assignee
세다르스-신나이 메디칼 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터 filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020217026836A priority Critical patent/KR20210107176A/ko
Publication of KR20160009582A publication Critical patent/KR20160009582A/ko
Application granted granted Critical
Publication of KR102295125B1 publication Critical patent/KR102295125B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020157034355A 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체 Active KR102295125B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217026836A KR20210107176A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361824932P 2013-05-17 2013-05-17
US61/824,932 2013-05-17
PCT/US2014/038468 WO2014186750A2 (en) 2013-05-17 2014-05-16 Variants of tnfsf15 and dcr3 associated with crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217026836A Division KR20210107176A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Publications (2)

Publication Number Publication Date
KR20160009582A KR20160009582A (ko) 2016-01-26
KR102295125B1 true KR102295125B1 (ko) 2021-08-31

Family

ID=51899024

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020157034355A Active KR102295125B1 (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020237020524A Ceased KR20230093538A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020257028341A Pending KR20250130857A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020217026836A Ceased KR20210107176A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020237020524A Ceased KR20230093538A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020257028341A Pending KR20250130857A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR1020217026836A Ceased KR20210107176A (ko) 2013-05-17 2014-05-16 크론병과 연관된 tnfsf15와 dcr3의 변이체

Country Status (7)

Country Link
US (4) US20160090629A1 (https=)
EP (3) EP3988673A3 (https=)
JP (5) JP6482533B2 (https=)
KR (4) KR102295125B1 (https=)
CN (1) CN105358713B (https=)
ES (1) ES2894963T3 (https=)
WO (1) WO2014186750A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
KR20230109779A (ko) 2013-03-27 2023-07-20 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전
ES2894963T3 (es) 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
EP3730188B1 (en) 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
EP3458466B1 (en) * 2016-05-20 2024-08-07 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
KR20210057088A (ko) * 2018-09-07 2021-05-20 더 칠드런스 호스피탈 오브 필라델피아 림프계 장애의 진단 및 치료를 위한 조성물 및 방법
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
CN121930331A (zh) * 2019-09-13 2026-04-28 协和麒麟株式会社 DcR3变体
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105590A2 (en) * 2008-02-19 2009-08-27 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
US20120073585A1 (en) 2009-04-08 2012-03-29 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20090186034A1 (en) * 2006-12-19 2009-07-23 Genetech, Inc. Gene expression markers for inflammatory bowel disease
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
NZ609363A (en) 2010-10-18 2015-04-24 Nestec Sa Methods for determining anti-drug antibody isotypes
CA2827609A1 (en) 2011-02-17 2012-11-15 Nestec S.A. Assays for detecting autoantibodies to anti-tnf.alpha. drugs
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
EP2565277A1 (en) 2011-09-05 2013-03-06 Progenika Biopharma, S.A. Method for predicting radiographic severity in ankylosing spondylitis
JP2015502740A (ja) 2011-10-21 2015-01-29 ネステク ソシエテ アノニム 炎症性腸疾患の診断を改善するための方法
ES2894963T3 (es) 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
WO2009105590A2 (en) * 2008-02-19 2009-08-27 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
US20120073585A1 (en) 2009-04-08 2012-03-29 Cedars-Sinai Medical Center Methods of predicting complication and surgery in crohn's disease
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics
WO2012161856A1 (en) 2011-05-20 2012-11-29 Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gastroenterology (2008) 135:552-567*
Gastroenterology (2013) 144(5):S-466
Human Molecular Genetics (2005) 14(22):3499-3506
Inflammatory Bowel Diseases (2013.02.06.) 19(3):526-533*
Mucosal Immunology (2011) 4:172-185
PLoS ONE (2012) 7(12):e52223*

Also Published As

Publication number Publication date
US20160090629A1 (en) 2016-03-31
US12281359B2 (en) 2025-04-22
JP2016526875A (ja) 2016-09-08
JP6482533B2 (ja) 2019-03-13
JP2025023316A (ja) 2025-02-14
KR20250130857A (ko) 2025-09-02
EP3988673A3 (en) 2022-08-03
US20250243548A1 (en) 2025-07-31
JP2018148931A (ja) 2018-09-27
KR20230093538A (ko) 2023-06-27
KR20210107176A (ko) 2021-08-31
JP2020127437A (ja) 2020-08-27
EP3988673A2 (en) 2022-04-27
ES2894963T8 (es) 2022-02-24
US20180230543A1 (en) 2018-08-16
CN105358713B (zh) 2020-02-28
EP3498867B1 (en) 2021-09-29
CN105358713A (zh) 2016-02-24
EP2997165A2 (en) 2016-03-23
JP2022111329A (ja) 2022-07-29
WO2014186750A2 (en) 2014-11-20
EP2997165A4 (en) 2017-03-08
ES2894963T3 (es) 2022-02-16
WO2014186750A3 (en) 2015-01-08
US20210371931A1 (en) 2021-12-02
EP3498867A1 (en) 2019-06-19
KR20160009582A (ko) 2016-01-26

Similar Documents

Publication Publication Date Title
KR102295125B1 (ko) 크론병과 연관된 tnfsf15와 dcr3의 변이체
KR20180127416A (ko) Rnaset2를 통한 염증성 장 질환의 진단 방법
JP2015516979A (ja) Ｃｒｈ過剰活性を有する患者の治療に用いるためのｃｒｈｒ１アンタゴニスト
Grosjean et al. Autophagopathies: from autophagy gene polymorphisms to precision medicine for human diseases
US20160096885A1 (en) Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis
JP2016540729A (ja) 酢酸グラチラマーへの応答を予測する遺伝子マーカー
EP3011048B1 (en) Method for predicting a treatment response to a v1b antagonist in a patient with depressive and/or anxiety symptoms
Glas et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease
Zhang et al. Identification of two novel mutations in three Chinese families with Kallmann syndrome using whole exome sequencing
DK3277835T3 (en) GENETIC PREDICTORS OF A REACTION ON TREATMENT WITH CRHR1 ANTAGONISTS
AU2016240213B2 (en) Method of treatment using genetic predictors of a response to treatment with CRHR1 antagonists
Szczepańska et al. Involvement of vascular endothelial growth factor− 460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis
Sakalar et al. Higher frequency of rs4977574 (the G Allele) on chromosome 9p21. 3 in patients with myocardial infarction as revealed by PCR-RFLP analysis
Waugh et al. Interferon receptor gene dosage determines diverse hallmarks of Down syndrome
JPWO2013103094A1 (ja) コフィン−シリス症候群の検出方法
HK40072596A (en) Variants of tnfsf15 and dcr3 associated with crohn's disease
TW201701897A (zh) 選擇對醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之反應具預測性之單一核苷酸多型性
Seo et al. Mutation spectrum of RB1 gene in Korean bilateral retinoblastoma patients using direct sequencing and gene dosage analysis.
Davatchi et al. HLA-B51 in Behçet’s disease
WO2016141441A1 (en) Treatment and detection of inflammatory disease
Zhou et al. Epigenome-wide Association Study (EWAS) of BMI, BMI Change, and Waist Circumference in African American Adults Identifies Multiple Replicated Loci

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190516

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200506

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20201111

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210524

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210824

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210824

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210825

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20250625

Start annual number: 5

End annual number: 5